Stock Price
1.35
Daily Change
0%
Yearly
-35.71%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agenus 3.15 0 0% -17.11%
Baxter International 74.57 -1.46 -1.92% -1.24%
Bluebird Bio 10.11 -0.22 -2.13% -77.96%
Cytokinetics 39.34 0.57 1.47% 124.29%
Plus Therapeutics, Inc. 1.50 0 0% -27.18%
Genocea Biosciences 1.35 0 0% -35.71%
Glaxosmithkline 41.12 -0.24 -0.58% 9.59%
Infinity Pharmaceuticals 2.17 0.08 3.83% 5.85%
Merck & Co 74.91 0.02 0.03% -8.14%
Moderna Inc 352.43 -16.08 -4.36% 149.93%
Mirati Therapeutics 136.77 0.77 0.57% -41.64%
Novavax 208.63 14.67 7.56% 68.97%
Pfizer 53.73 1.33 2.54% 36.34%
Prothena 50.15 0.93 1.89% 355.91%

Indexes Price Day Year
NASDAQ 15538 -245.14 -1.55% 25.76%
US2000 2199 -43.07 -1.92% 19.76%

Genocea Biosciences
Genocea Biosciences, Inc. is a biopharmaceutical company that is engaged in discovering and developing cancer immunotherapies using its Antigen Lead Acquisition System (ATLAS) technology platform. The Company’s Antigen Lead Acquisition System (ATLAS) technology platform allows to identify targets based on each person’s tumor antigen-specific T cell responses. Its programs include GEN-009 is a neoantigen vaccine candidate delivering adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. Its GEN-011 program is an adoptive T cell therapy using neoantigen-targeted peripheral T cells (NPTs). The GEN-011 NPTs is preferred for ATLAS-identified anti-tumor antigens that are used to manufacture a peripheral blood-derived, tumor-specific T cell therapy.